后疫情时代血液恶性肿瘤或接受细胞治疗患者COVID-19管理建议:欧洲白血病感染会议(ECIL-10)
ECIL-10发布后疫情时代血液恶性肿瘤或接受造血干细胞移植及细胞治疗患者COVID-19管理建议。SARS-CoV-2致病性减弱但此类患者仍高危,诊断以鼻口咽拭子核酸检测为金标准,阳性抗原检测可快速决策但敏感性低。预防以主动免疫为关键,有症状者早期抗病毒可能降低重症风险。
要点
- 鼻口咽拭子核酸检测为诊断金标准,阳性抗原检测可快速决策但敏感性低。
- 主动免疫是预防关键,可能需每年匹配流行变异株。
- 有症状患者早期使用奈玛特韦/利托那韦或瑞德西韦可能降低重症风险。
核心结论
- 后疫情时代血液恶性肿瘤或接受细胞治疗患者仍面临不良结局高风险,需坚持接触和飞沫防护。
- 主动免疫是预防关键,可能需每年匹配流行变异株。
- 有症状患者早期抗病毒治疗可能降低进展至重型-危重型COVID-19的风险。
研究设计与样本
- 欧洲白血病感染会议(ECIL-10)制定的后疫情时代管理建议。
主要发现
- SARS-CoV-2致病性和死亡率因致病性更弱的变异株、主动和被动免疫及抗病毒治疗而下降。
- 鼻口咽拭子核酸检测因高敏感性和特异性为诊断金标准。
- 直接抗原检测阳性可快速管理决策,但敏感性低,尤其无症状患者。
- SARS-CoV-2中和抗体被动免疫因免疫逃逸变异株出现已失去适应证。
- 恢复期血浆被提议用于被动免疫,但多数中心不易获得。
关键数值与推荐
- 有症状患者早期抗病毒治疗可选用奈玛特韦/利托那韦或瑞德西韦。
- 抗病毒单药治疗临床或病毒学失败者可考虑延长给药、重复疗程或联合抗病毒药物。
- 重型-危重型COVID-19推荐地塞米松或下调炎症细胞因子反应的药物(抗IL-6/抗IL-2药物、Janus激酶抑制剂),联合最佳支持和重症监护,免疫抑制患者需谨慎。
- COVID-19患者可考虑推迟强化化疗、HCT预处理、T细胞免疫治疗或T细胞衔接抗体;无症状确诊感染者推迟决策需个体化。
临床怎么用
- 接触和飞沫防护对避免传播至关重要,尤其疫情期间。
- 有症状患者早期抗病毒治疗可能降低进展至重型-危重型COVID-19的风险。
- 抗病毒单药治疗失败者可考虑延长给药、重复疗程或联合抗病毒药物。
- 重型-危重型患者推荐地塞米松或下调炎症细胞因子反应的药物联合最佳支持治疗。
- COVID-19患者可考虑推迟强化化疗、HCT预处理、T细胞免疫治疗或T细胞衔接抗体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the post-pandemic years, SARS-CoV-2 morbidity and mortality declined due to less pathogenic variants, active and passive immunization, and antiviral therapies. However, patients with hematological malignancies and/or undergoing hematopoietic cell transplantation (HCT) remain at increased risk for poor outcomes. Therefore, adherence to contact and droplet precautions is essential to avoid transmission, especially during epidemic waves. Detection of viral RNA by nucleic acid testing of naso-oro-pharyngeal samples is the gold standard for diagnosis due to its high sensitivity and specificity. Direct antigen testing allows for rapid management decisions if positive, but has a low sensitivity, especially in asymptomatic patients. Active immunisation is the key to prevention and may require annual matching to circulating variants. Passive immunization with SARS-CoV-2 neutralizing anti-antibodies lost its indication due to the emergence of immune escape variants. Convalescent plasma has been proposed for passive immunization but is not readily available in most centres. For symptomatic patients, early antiviral treatment with nirmatrelvir/ritonavir or remdesivir may reduce the risk of progression to severe-critical COVID-19. Prolonged administration, repeated courses, and a combination of antivirals are considered for patients with clinical or virological failure to antiviral monotherapy. In severe-critical COVID-19, dexamethasone or drugs downregulating the inflammatory cytokine responses (anti-Il-6/anti-IL-2 agents, Janus kinase inhibitor) are recommended, together with the best supportive and intensive care, but care should be exercised in immunosuppressed patients. Deferral of intensive chemotherapy, HCT conditioning, T-cell-based immunotherapy, or T-cell engaging antibodies are considered for patients with COVID-19, whereas deferral decisions are taken on a case-by-case basis for asymptomatic patients with confirmed SARS-CoV-2 infection.
引用
- Cesaro S, Ljungman P, Mikulska M, et al. Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-10). Leukemia. 2025. PMID: 40456838. doi:10.1038/s41375-025-02649-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。